Cancer Testing · us
Searching for Cancer Signals in Blood: Natera’s Multi-Cancer Early Detection Test Receives FDA Breakthrough Device Designation
Data covering 12 cancer types have secured Natera closer FDA support during development and an opportunity for priority review. But test accuracy, the study population, and the submission timeline remain undisclosed, leaving key questions about screening benefits unresolved.
Finding signs of multiple cancers through a single blood draw is the goal of multi-cancer early detection; the real test is whether a detected signal can accurately guide subsequent diagnosis. On October 9, 2026, Natera announced that its multi-cancer early detection test had received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA), marking a new regulatory development for this blood-based screening technology.
The test analyzes cell-free DNA (cfDNA) in blood to screen for multiple cancers. According to Natera’s announcement, the FDA evaluated data covering 12 cancer types, considering sensitivity, specificity, and performance in determining the source of cancer signals. RTTNews also relayed these evaluation criteria in its report on the same day but provided no additional validation data.
The three measures answer different questions: sensitivity concerns whether cancer can be detected when it is present, specificity concerns whether false positives can be avoided when cancer is absent, and signal source determination attempts to identify the tissue or organ from which the cancer may originate. OncLive explained that this localization function is intended to help guide subsequent diagnostic testing after a positive signal is detected; a warning signal in blood still requires further investigation.
However, outside observers currently cannot assess how accurate the test actually is. OncLive noted that the announcement did not disclose numerical values for sensitivity, specificity, or signal source determination, nor did it list the names of the 12 cancer types or describe the study population. Data covering 12 cancer types therefore do not establish equal detection capability for each type, and cannot be used to extrapolate performance in a general screening setting.
Breakthrough Device designation allows developers to communicate more closely with FDA experts during development and gives subsequent premarket submissions priority review. The designation itself does not constitute FDA marketing authorization or approval, nor can it be taken as direct confirmation of clinical benefit. For Natera, the immediate progress primarily consists of support for the development and review processes.
Public details remain scarce about which studies the test will need to demonstrate its value. OncLive noted that Natera did not announce a timeline for its premarket submission or describe the studies planned to support its registration submission. For multi-cancer early detection, finding more signals is only the starting point; whether the test can reliably detect cancer in its intended population, reduce false positives, and connect positive results to an effective diagnostic pathway is the next level of evidence needed to assess the technology’s practical utility.